The World Health Organization (WHO) has backed a Covid-19 treatment developed by Swiss pharmaceutical giant Roche and United States biotech company Regeneron.
This content was published on
2 minutes
swissinfo.ch/mga
Español
es
COVID-19: La OMS aprueba tratamiento Roche/Regeneron
WHO also made it clear that it wants both companies to make the treatment available to low income countries at an affordable price.
Roche and Regeneron have collaborated on producing the treatment using the monoclonal antibodies casirivimab and imdevimab, which have been shown to be effective at neutralising the virus when combined.
WHO on Friday recommended that the treatment be used on infected people who either have underlying health conditions or are suffering from severe symptoms.
The health body has urged both companiesExternal link to “address the high price and limited production” of the treatment. It is asking Roche for “a donation and distribution of the drug through UNICEF”.
The global health agency UNITAID is also negotiating with the manufacturers to grant access to the drug for less well-off countries.
“The need to have effective treatments for Covid-19 has never been greater, with many countries around the world facing case surges driven by Delta and other variants,” UNITAID stated on Friday. “These surges are having a particularly devastating impact on low- and middle- income countries, which continue to have limited access to vaccines.”
The agency welcomed an initial donation from Roche and Regeneron to meet this challenge but argued for a more sustainable solution. “Broader access commitments are needed from industry to ensure that pricing and supply conditions enable this product to reach all people regardless of where they live.”
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
What factors should be taken into account when inheriting Swiss citizenship abroad?
Should there be a limit to the passing on of Swiss citizenship? Or is the current practice too strict and it should still be possible to register after the age of 25?
This content was published on
Swiss imports and exports reached new heights in the first quarter, driven by the chemicals and pharmaceuticals sectors. Shipments to the US rose sharply.
Italian in Switzerland accused of being Calabrian mafia henchman
This content was published on
The Office of the Attorney General of Switzerland has charged an Italian resident of the Anello-Fruci 'Ndrangheta clan in the canton of Aargau.
Swiss CFOs have a pessimistic outlook due to trade wars
This content was published on
In the wake of the trade wars launched by US President Donald Trump, Swiss companies are assessing the future much more pessimistically.
Swiss parcel bomber had links to military and intelligence services
This content was published on
The 61-year-old man who admitted to being Patek Philippe's blackmailer in Geneva had connections in the police and the army.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche bids to co-develop potential oral Covid-19 treatment
This content was published on
The Basel-based company has partnered with Atea Pharmaceuticals to develop, manufacture and distribute the latter’s oral anti-Covid-19 treatment.
WHO and Roche launch trials of potential coronavirus treatments
This content was published on
Roche is launching a clinical trial of a potential new Covid-19 drug, adding to rapidly growing investments in combating coronavirus.
Chair of pharma firm Roche advocates mandatory Covid-19 vaccination
This content was published on
Christoph Franz said he was in favour of compulsory jabs if vaccination coverage rates were insufficient and if there was a social consensus.
Roche rheumatism drug does not reduce Covid-19 deaths
This content was published on
Swiss pharma firm Roche says a drug normally used to treat other medical conditions has failed to prove its effectiveness at alleviating the symptoms of Covid-19.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.